Sanofi US Services INC (Formerly Known as Genzyme Corporation)

A bio company focused on developing and applying advanced technologies in the life science

Based in DC

🤖

AI Overview

With $1.9M in lobbying spend across 31 quarterly filings, Sanofi US Services INC (Formerly Known as Genzyme Corporation) is a significant lobbying presence. They deploy 12 individual lobbyists

$1.9M

Total Lobbying Spend

Quarterly Filings

Lobbying Firms Used

Individual Lobbyists

Spending by Year

Year	Lobbying Spend
2018	$250K
2019	$240K
2020	$240K
2021	$180K
2022	$300K
2023	$240K
2024	$180K
2025	$240K

Lobbying Firms

TARPLIN, DOWNS & YOUNG, LLC

What They Lobby For

budget resolution, reconciliation, deficit reduction, debt ceiling, apropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018
orphan drug tax credit
Patent reform
PL 114-255 - 21st Century Cures, implementation H.R. 878/S. 204 - Right to Try Act H.R. 1231/S. 456 - RACE for Children Act H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act ***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB
***, no specific bill(s), Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, home infusion, Least Costly alternative, Part B, ASP, insulin access, vaccines, flu
PL 114-255 - 21st Century Cures, implementation H.R. 878/S. 204 - Right to Try Act H.R. 1231/S. 456 - RACE for Children Act H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act S. 2852 - Pandemic and All Hazards Preparedness Act S.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act ***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB
***, no specific bill(s), Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, home infusion, Least Costly alternative, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability
budget resolution, reconciliation, deficit reduction, debt ceiling, apropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution
PL 114-255 - 21st Century Cures, implementation H.R. 878/S. 204 - Right to Try Act H.R. 1231/S. 456 - RACE for Children Act H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 849/S. 260 - Protecting Seniors' Access to Medicare Act S. 2852 - Pandemic and All Hazards Preparedness Act S.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act H.R. 6 - SUPPORT for Patients and Communities Act ***no specific bills, importation, supply chain integrity, 304b, biosimilars, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, IPAB
budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution H.R. 695 - Department of Defense Appropriations Act